Prelude Therapeutics Incorporated (PRLD)
Prelude Therapeutics Incorporated operates in the Biotechnology industry of the Healthcare sector, headquartered in Wilmington, DE, US. The stock last traded at $5.49, up 3.10% on the session, giving a market capitalisation of $312.3M. On trailing twelve-month figures it carries a trailing P/E of -6.94, a net margin of -269.7%. Its beta of 0.95 implies it has historically moved less than the broad market.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Prelude Therapeutics Incorporated is most often compared with the following Healthcare names: